Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.05.18	Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO (PR Newswire)
16.05.18	Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis (PR Newswire)
16.05.18	Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints (RTTNews)
16.05.18	Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis (PR Newswire)
03.05.18	Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates (RTTNews)
03.05.18	Regeneron Reports First Quarter 2018 Financial and Operating Results (PR Newswire)
02.05.18	DocPanel Announces Partnership with the University of Southern California Keck School of Medicine (PR Newswire)
01.05.18	2018 Global Channel Report Reveals Clients Attacked Mostly Through Privileged Accounts (PR Newswire)
01.05.18	Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts (RTTNews)
01.05.18	Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients (PR Newswire)
01.05.18	Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients (PR Newswire)
01.05.18	INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM (RTTNews)
30.04.18	Regeneron And Sanofi Say FDA Accepts Priority Review BLA For Cemiplimab (RTTNews)
30.04.18	FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
30.04.18	FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
23.04.18	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)
18.04.18	ARTiFACTS and Blockchain in Healthcare Today Partner to Expand Use of Blockchain in Scholarly Publishing (PR Newswire)
09.04.18	Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018 (PR Newswire)
06.04.18	American Financial Benefits Center on Debt-Free College and Existing Repayment Options (PR Newswire)
03.04.18	Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN (RTTNews)
03.04.18	EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma (PR Newswire)
03.04.18	EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
03.04.18	Caroline S. Koblenzer is recognized by Continental Who's Who (PR Newswire)
22.03.18	FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY Team Up For NASH (RTTNews)
21.03.18	Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH) (PR Newswire)
21.03.18	Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease (PR Newswire)
19.03.18	Regeneron Reports Positive Results From Phase 3 PANORAMA Trial With EYLEA (RTTNews)
19.03.18	EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial (PR Newswire)
14.03.18	Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease (PR Newswire)
12.03.18	SVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch (RTTNews)
11.03.18	An Ear To The Pharma: 4 Stocks To Watch This Week (RTTNews)
10.03.18	Regeneron, Sanofi To Cut Heart Drug's Price; Say Praluent Lowers Risk Of Death (RTTNews)
10.03.18	Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need (PR Newswire)
10.03.18	Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need (PR Newswire)
10.03.18	Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate (PR Newswire)
10.03.18	Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate (PR Newswire)
04.03.18	An Ear To The Pharma: 7 Stocks To Watch This Week (RTTNews)
02.03.18	Sanofi: FDA prüft Antrag für Dupilumab für Asthma-Behandlung (Dow Jones)
02.03.18	Sanofi:FDA Reviews DUPIXENT As Potential Treatment For Moderate-to-Severe Asthma (RTTNews)
02.03.18	FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma (PR Newswire)
12.02.18	Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial (PR Newswire)
08.02.18	Regeneron Pharmaceuticals Q4 Income Rises (RTTNews)
08.02.18	Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results (PR Newswire)
06.02.18	New Molecular Test to Impact Influenza Pandemic Preparedness (PR Newswire)
30.01.18	Camp Bow Wow Showcases Impressive Start to 2018, Ranking #1 in Pet Care on Entrepreneur's Franchise 500 List and More (PR Newswire)
26.01.18	James Flicker Joins Sagent Advisors as a Managing Director and Head of Paper & Forest Products (PR Newswire)
23.01.18	Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018 (PR Newswire)
23.01.18	Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018 (PR Newswire)
23.01.18	Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018 (PR Newswire)
22.01.18	Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus